245 related articles for article (PubMed ID: 24934886)
21. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan.
Kawai S; Ochi M; Nakagawa T; Goto H
J Infect Chemother; 2004 Dec; 10(6):352-8. PubMed ID: 15614461
[TBL] [Abstract][Full Text] [Related]
22. Importance of atypical pathogens of community-acquired pneumonia.
Plouffe JF
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
[TBL] [Abstract][Full Text] [Related]
23. The role of atypical pathogens in community-acquired pneumonia.
Gupta SK; Sarosi GA
Med Clin North Am; 2001 Nov; 85(6):1349-65, vii. PubMed ID: 11680106
[TBL] [Abstract][Full Text] [Related]
24. Chlamydia pneumoniae and Mycoplasma pneumoniae.
Blasi F; Tarsia P; Aliberti S; Cosentini R; Allegra L
Semin Respir Crit Care Med; 2005 Dec; 26(6):617-24. PubMed ID: 16388430
[TBL] [Abstract][Full Text] [Related]
25. C-reactive protein for discriminating treatment failure from slow responding pneumonia.
Ruiz-González A; Falguera M; Porcel JM; Martínez-Alonso M; Cabezas P; Geijo P; Boixeda R; Dueñas C; Armengou A; Capdevila JA; Serrano R
Eur J Intern Med; 2010 Dec; 21(6):548-52. PubMed ID: 21111942
[TBL] [Abstract][Full Text] [Related]
26. [Determination of serologic markers against bacterial atypical pneumonia agents in pneumonia patients].
Pinar A; Ercis S; Ulukavak T; Dursun B; Hasçelik G
Mikrobiyol Bul; 2004; 38(1-2):27-32. PubMed ID: 15293899
[TBL] [Abstract][Full Text] [Related]
27. Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy.
Miyashita N; Higa F; Aoki Y; Kikuchi T; Seki M; Tateda K; Maki N; Uchino K; Ogasawara K; Kiyota H; Watanabe A
J Infect Chemother; 2017 Nov; 23(11):727-732. PubMed ID: 28951197
[TBL] [Abstract][Full Text] [Related]
28. Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?
Johnston SL; Martin RJ
Am J Respir Crit Care Med; 2005 Nov; 172(9):1078-89. PubMed ID: 15961690
[TBL] [Abstract][Full Text] [Related]
29. Clinical inquiries. What is the best macrolide for atypical pneumonia?
Neher JO; Morton JR; Mouw D
J Fam Pract; 2004 Mar; 53(3):229-30. PubMed ID: 15000931
[No Abstract] [Full Text] [Related]
30. Atypical bacterial pathogens in community-acquired pneumonia in children: a hospital-based study.
Agarwal J; Awasthi S; Rajput A; Tiwari M; Jain A
Trop Doct; 2009 Apr; 39(2):109-11. PubMed ID: 19299299
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
[TBL] [Abstract][Full Text] [Related]
32. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].
Sáez-Llorens X; Castaño E; Wubbel L; Castrejón MM; de Morales I; Vallarino D; de Atencio I; Muñiz L; Olsen K; McCracken GH
Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand.
Phares CR; Wangroongsarb P; Chantra S; Paveenkitiporn W; Tondella ML; Benson RF; Thacker WL; Fields BS; Moore MR; Fischer J; Dowell SF; Olsen SJ
Clin Infect Dis; 2007 Dec; 45(12):e147-55. PubMed ID: 18190309
[TBL] [Abstract][Full Text] [Related]
34. [Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia].
Fujiki R; Rikimaru T; Aizawa H; Kawayama T
Jpn J Antibiot; 2003 Dec; 56(6):712-8. PubMed ID: 15007880
[TBL] [Abstract][Full Text] [Related]
35. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
Lopez Sisniega J; Profant M; Kostrica R; Waskin H
Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
[TBL] [Abstract][Full Text] [Related]
36. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua.
Matute AJ; Brouwer WP; Hak E; Delgado E; Alonso E; Hoepelman IM
Int J Antimicrob Agents; 2006 Nov; 28(5):423-7. PubMed ID: 17046211
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial.
Miyazaki T; Nakamura S; Hashiguchi K; Kobayashi T; Fukushima K; Fukuda Y; Kondo A; Inoue Y; Koga H; Sasaki E; Nagayoshi Y; Higashiyama Y; Yoshida M; Takazono T; Saijo T; Morinaga Y; Yamamoto K; Imamura Y; Mikushi S; Izumikawa K; Yanagihara K; Kohno S; Mukae H
J Infect Chemother; 2019 Nov; 25(11):886-893. PubMed ID: 31113725
[TBL] [Abstract][Full Text] [Related]
38. Mycoplasma pneumoniae and community-acquired pneumonia.
Dey AB; Chaudhry R; Kumar P; Nisar N; Nagarkar KM
Natl Med J India; 2000; 13(2):66-70. PubMed ID: 10835852
[TBL] [Abstract][Full Text] [Related]
39. Predicting Mycoplasma pneumoniae and Chlamydophila pneumoniae in community-acquired pneumonia (CAP) pneumonia: epidemiological study of respiratory tract infection using multiplex PCR assays.
Ishimaru N; Suzuki S; Shimokawa T; Akashi Y; Takeuchi Y; Ueda A; Kinami S; Ohnishi H; Suzuki H; Tokuda Y; Maeno T
Intern Emerg Med; 2021 Nov; 16(8):2129-2137. PubMed ID: 33983474
[TBL] [Abstract][Full Text] [Related]
40. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
